Lusutrombopag (Mulpleta, S-888711) is an oral bioavailable thrombopoietin (TPO) receptor agonist being investigated for the treatment of chronic liver disease (CLD).

 

Brand: BCM

 

Target: Thrombin; Thrombopoietin Receptor

 

Signaling Pathways: Immunology/Inflammation; Proteases/Proteasome

 

In Vitro: Lusutrombopag is an agonist of the thrombopoietin receptor that activates platelet production. Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels.

 

pKa: 4.33±0.21(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

GHS: GHS07

 

Isomeric SMILES: CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\C)/C(=O)O)Cl  

 

InChIKey: NOZIJMHMKORZBA-KJCUYJGMSA-N  

 

InChI: InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1

 

Attribute
[Chem Name]	(E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
[Synonym]	Lusutrombopag; Mulpleta; S-888711
[CAS No.]	1110766-97-6
[MDL No.]	MFCD28502075
[Formula]	C29H32Cl2N2O5S
[Molecular]	591.55
[Form]	A crystalline solid
[Storage]	Sealed in dry. Room Temperature

Goods Tag